Results 131 to 140 of about 2,944,639 (323)
Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann +15 morewiley +1 more sourceEditor comment
, 2018 Corinne Le Quéré, R. Andrew, J. Canadell, S. Sitch, J. I. Korsbakken, G. Peters, A. Manning, T. Boden, P. Tans, R. Houghton, R. Keeling, S. Alin, Oliver Andrews, P. Anthoni, L. Barbero, L. Barbero, L. Bopp, F. Chevallier, L. Chini, P. Ciais, K. Currie, C. Delire, S. Doney, P. Friedlingstein, T. Gkritzalis, I. Harris, J. Hauck, V. Haverd, M. Hoppema, K. K. Goldewijk, A. Jain, Etsushi Kato, A. Körtzinger, P. Landschützer, N. Lefèvre, A. Lenton, Sebastian Lienert, Sebastian Lienert, D. Lombardozzi, J. Melton, N. Metzl, F. Millero, P. Monteiro, D. Munro, J. Nabel, S. Nakaoka, K. O’Brien, A. Olsen, A. Omar, T. Ono, D. Pierrot, D. Pierrot, B. Poulter, B. Poulter, C. Rödenbeck, J. Salisbury, U. Schuster, J. Schwinger, R. Séférian, I. Skjelvan, B. Stocker, A. Sutton, A. Sutton, Taro Takahashi, H. Tian, B. Tilbrook, I. V. D. Laan-Luijkx, G. Werf, N. Viovy, A. Walker, A. Wiltshire, S. Zaehle +71 moresemanticscholar +1 more sourceClass IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio +13 morewiley +1 more sourceSait ölmüş [PDF]
Taha Toros Arşivi, Dosya No: 5-Sait Faik Abasıyanıkİstanbul Kalkınma Ajansı (TR10/14/YEN/0033) İstanbul Development Agency (TR10/14/YEN ...Üstün, Nevzatcore Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Molecular Oncology, EarlyView.Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix +13 morewiley +1 more sourceMolecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines
Molecular Oncology, EarlyView.Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed +12 morewiley +1 more source
